Squarepoint
NRSN icon

Squarepoint’s NeuroSense Therapeutics NRSN Stock Holding History

Squarepoint’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,926
Closed -$13.8K – 4726
2025
Q4 		$13.8K Sell
17,926
-77,449
-81% -$81.5K ﹤0.01% 4180
2025
Q3 		$119K Buy
95,375
+45,450
+91% +$66.5K ﹤0.01% 4077
2025
Q2 		$94.4K Buy
+49,925
New +$72.3K ﹤0.01% 4178

Other funds holding NRSN

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's NRSN Position: Q1 2026 in Review

Squarepoint sold out of NeuroSense Therapeutics (NRSN) in Q1 2026, closing a stake of 17,926 shares — an estimated $13.8K sold.

Squarepoint first reported a position in NRSN in Q2 2025 and held it in 3 quarters. The position peaked at $119K in Q3 2025. 13 funds tracked by Wall St. Rank hold NRSN as of Q1 2026.

  • Squarepoint reported no remaining NeuroSense Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 17,926 NeuroSense Therapeutics shares in Q1 2026, an estimated $13.8K.
  • Squarepoint first reported a position in NeuroSense Therapeutics in Q2 2025 and held it in 3 quarters.
  • Squarepoint's NeuroSense Therapeutics position peaked at $119K in Q3 2025.
  • 13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.